


AMENDMENTS

In the Claims:

Claims 1-2. (Canceled).

3. (Currently amended) A compound of formula II,



wherein

Ar^1 is selected from the group consisting of phenyl, pyridinyl, quinolinyl, isoquinolinyl, thiophenyl, benzothiadiazolyl, isoxazolyl and oxazolyl,

Ar^2 is pyridinyl,

R^6, R^7 are independently H or A,

R^8, R^9 and R^{10} are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$,

$(\text{CH}_2)_n\text{COOR}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$, $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_u\text{R}^{13}$,
 $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $\text{CH}=\text{N}-\text{OA}$,
 $\text{CH}_2\text{CH}=\text{N}-\text{OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N}-\text{R}^{11}$,
 $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{13}$,
 $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$,
 $\text{CH}=\text{CHCH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}$
and $(\text{CH}_2)_n\text{NCO}$, wherein

R^{11} , R^{12} are independently selected from the group consisting of H, A and (CH_2) ,

R^{13} , R^{14} are independently selected from the group consisting of H, Hal, A and $(\text{CH}_2)_m\text{Ar}^4$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylencycloalkyl, alkoxy and alkoxyalkyl,

Ar^3, Ar^4 are independently aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2 , CN, OR^{15} , $\text{NR}^{15}\text{R}^{16}$, COOR^{15} , $\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S(O)}_u\text{A}$ and OOCR^{15} ,

$\text{R}^{15}, \text{R}^{16}$ are independently selected from the group consisting of H, A, and $(\text{CH}_2)_m\text{Ar}^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3 ,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X is O or CH_2 ,

Y is O or S ~~selected from O and S~~,

p, r are independently 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,




u is 0, 1, 2 or 3,






and






Hal is selected from the group consisting of F, Cl, Br and I;






and a pharmaceutically acceptable salt derivatives, ~~salts and solvates~~ thereof.



4. (Currently Amended) The compound according to claim 3, selected from the compounds of formula IIc, IIe, IIg, IIh, Ili, IIj, IIk, IIL, IIm, IIn, Ilo, IIp, IIq, IIr, IIs, IIu, IIv, IIw and IIx,











wherein R^6 , R^7 , R^8 , p , Ar^1 , Y , X , R^9 , R^{10} and q are as defined in claim 3 and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

5. (Currently amended) The compound according to claim 4 3, selected from the compounds (1) to (224) of table 1, the compounds (225) to (448) ~~(449)~~ of table 2 and/or the compounds (449) ~~(450)~~ to (672) of table 3, and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

Claims 6-9. (Canceled).

10. (Currently Amended) A pharmaceutical composition, comprising the compound according to claim 3 in a pharmaceutical composition and further comprising an inert carrier.
11. (Withdrawn/Previously presented) The pharmaceutical composition according to claim 10, wherein it contains one or more additional compounds, selected

from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.

12. (Withdrawn/Previously presented) A process for manufacture of a pharmaceutical composition, wherein one or more compounds according to claim 3 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients, are processed by mechanical means into a pharmaceutical composition that is suitable as a dosage form for application and/or administration to a patient.

Claims 13-29. (Canceled).

30. (Withdrawn/Previously presented) A method for producing compounds of formula II, wherein

- a) a compound of formula III




wherein

FG is a functional group, selected from
-N=C=Y and -NH-(C=Y)-LG,
wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

- b) with a compound of IV,



wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^6 , R^7 ,
 E , G , M , Q , U , R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 3,

and optionally

- c) isolating and/or treating the compound of formula II obtained by
said reaction with an acid, to obtain the salt thereof.

Claims 31-32. (Canceled).